About Us

About BioXpress Therapeutics

BioXpress Therapeutics SA is exclusively focused on the development of biosimilars. With a philosophy that everyone should have access to high quality biologic therapeutics, BioXpress brings speed, efficiency and safety in developing biosimilar mAbs that impact patients’ quality of life. The Company was founded by seasoned industry leaders in cell-line development and analytical characterization. From asset identification to manufacturing, characterization, clinical and regulatory developments, the Company has built a unique team of world-class experts.

BioXpress Therapeutics is activity seeking alliances with other biopharmaceutical companies and health organizations to accelerate the development of biosimilar therapeutics. We are already engaged in collaborations with partners from various countries and would like to hear from you. Please CONTACT US for pipeline partnership opportunities.

World-Class Leadership

BioXpress Therapeutics brings speed, efficiency and safety in sustainably manufactured biosimilars that impact
patients’ quality of life.

Pipeline Overview

BioXpress has co-developed five (5) biosimilar mAbs with different companies worldwide: BXT 2318 trastuzumab (Herceptin), BXT 1523 alemtuzuman (Lemtrada), BXT 2316 bevacizumab (Avastin), BXT 2922 adalimumab (Humira) and BXT 2336 rituximab (Rituxan).

Biosimilar Industry Overview

What generic drugs were to the global healthcare system in the 20th century is what biosimilars will become in the 21st century.

Biosimilars is are of the fastest growing segments of biologics (innovator or reference drugs). The term biologics refers to a wide range of therapeutic drugs that are manufactured in living systems. Monoclonal antibodies (mAbs) comprise of one class of biologics. A biosimilar may be considered a ‘generic’ of the innovator drug. A biosimilar can be launched when the innovator’s patent expires, provided the demonstration of its similarity is validated in terms of characteristics, efficiency and safety. In 2019, biosimilar monoclonal antibody drugs accounted for more than $3.3 billion USD in global drug sales and is projected to reach $16.2 billion USD by the end of 2025, growing at a CAGR of 25.2% over the forecast period.[1] The increase in number of mAb approvals for the treatment of cancer and autoimmune diseases has resulted in a high demand for monoclonal antibodies, fueling the business growth.

[1] Global Biosimilars Market Report, 2025 by Global Markets Insights